Zobrazeno 41 - 50
of 128
pro vyhledávání: '"Adrian Cook"'
Autor:
K. Wollschlaeger, Timothy J. Perren, Jacobus Pfisterer, Alexandra Leary, Gabe S. Sonke, Gilles Freyer, O. Tome, Olivier Colomban, L. Van Wagensveld, R. Kruitwagen, M. Van Der Aa, Michel Tod, M-C. Kaminsky-Forrett, Benoit You, Adrian Cook, A. du Bois, Frédéric Selle, Alain Lortholary, Florence Joly
Publikováno v:
Annals of Oncology. 31:S616
Autor:
AS Walker, Margaret J. Thomason, Moira J. Spyer, Adrian Cook, Patricia Nahirya-Ntege, Immaculate Nankya, Lincoln Mugarura, Diana M. Gibb, Bethany Naidoo-James, Emmanuel Ndashimye, Navdeep K. Thoofer, Victor Musiime, Tawanda Mhute, Marshall Munjoma, Wendy Snowden, Philip Kasirye
Publikováno v:
AIDS. 30:1761-1770
Background Antiretroviral therapy (ART) adherence is critical for successful HIV treatment outcomes. Once-daily dosing could improve adherence. Plasma concentrations of once-daily vs twice-daily abacavir + lamivudine are bioequivalent in children, bu
The Cost-Effectiveness of Bevacizumab in Advanced Ovarian Cancer Using Evidence from the ICON7 Trial
Autor:
Andrew C. Embleton, Sebastian Hinde, Timothy J. Perren, David Epstein, Adrian Cook, Mark Sculpher
Publikováno v:
Value in Health. 19:431-439
Background Bevacizumab is used extensively in the treatment of cancer, including advanced ovarian cancer, for which results of the International Collaborative Ovarian Neoplasm (ICON) 7 trial have been recently reported. The National Institute for Hea
Autor:
Paolo Denti, Helen McIlleron, Cissy Kityo, Adrian Cook, Adeniyi Olagunju, Andrew Owen, David M. Burger, Lubbe Wiesner, Veronica Mulenga, Andrzej Bienczak, Addy Kekitiinwa, A. Sarah Walker, Diana M. Gibb
Publikováno v:
British Journal of Clinical Pharmacology. 82:185-198
AIM: To characterise the efavirenz steady-state pharmacokinetics in African children using model-based approach, quantifying demographic and genotypic effects on the drug's disposition, and conduct simulations allowing prediction of optimised doses o
Autor:
Duncan C. Gilbert, Joanna Gale, Nicholas D. James, Shaun Tolan, Claire Amos, Robin Millman, Zafar Malik, G. Attard, James D. Wylie, Anjali Zarkar, S. Rudman, Robert Jones, Anna Lydon, Noel W. Clarke, Chris Parker, Joe M O'Sullivan, Jan Wallace, Aurelius Omlin, Alison Birtle, Adrian Cook, Archie Macnair, Malcolm David Mason, A.W.S. Ritchie, Matthew S. Simms, Alex Hoyle, Adnan Ali, H. Rush, John Wagstaff, Christopher D. Brawley, Jacob Tanguay, Andrew Protheroe, Silke Gillessen, Ruth E Langley, F.C. Ingleby, Omi Parikh, Stephanie Gibbs, David P. Dearnaley, David Matheson, Matthew R. Sydes, William Cross, Simon Chowdhury, L. Capaldi, Sharon Beesley, J. Calvert, Janet E. Brown, J.M. Russell, Hassan Douis, Narayanan Srihari, A. Nikapota, Mona Parmar, Stampede Investigators
Publikováno v:
Annals of Oncology. 31:442
Autor:
Duncan C. Gilbert, Christopher D. Brawley, H. Rush, Matthew R. Sydes, Gerhardt Attard, Robin Millman, Noel W. Clarke, Simon Chowdhury, Mahesh K. B. Parmar, Stampede Investigators, Adrian Cook, Nicholas D. James, Laura Murphy, Alicia K. Morgans, Ruth E Langley, David P. Dearnaley, Archie Macnair
Publikováno v:
Journal of Clinical Oncology. 38:14-14
14 Background: Docetaxel (DOC) and abiraterone (ABI) both improve overall survival (OS) in men with locally advanced or metastatic hormone-sensitive prostate cancer (HSPC) but no head to head trials compare the 2 agents. STAMPEDE, a multi-arm multi-s
Autor:
Hannah Mary Cheeseman, Suzanne Day, Leon Robert McFarlane, Sue Fleck, Aleisha Miller, Tom Cole, Nelson Sousa-Santos, Alethea Cope, Deniz Cizmeci, Monica Tolazzi, Edith Hwekwete, Drew Hannaman, Sven Kratochvil, Paul Francis McKay, Amy W. Chung, Stephen J. Kent, Adrian Cook, Gabriella Scarlatti, Sonya Abraham, Behazine Combadiere, Sheena McCormack, David John Lewis, Robin John Shattock
Publikováno v:
Human Gene Therapy
Human Gene Therapy, Mary Ann Liebert, 2018, 29 (9), pp.1011-1028. ⟨10.1089/hum.2018.075⟩
Human Gene Therapy, Mary Ann Liebert, 2018, 29 (9), pp.1011-1028. ⟨10.1089/hum.2018.075⟩
International audience; Intradermal (i.d.) and intramuscular (i.m.) injections when administered with or without electroporation (EP) have the potential to tailor the immune response to DNA vaccination. This Phase I randomized controlled clinical tri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::5b609fe0bbabee74087e63ccb8b75dee
https://hal.sorbonne-universite.fr/hal-02173181/file/hum.2018.075.pdf
https://hal.sorbonne-universite.fr/hal-02173181/file/hum.2018.075.pdf
Publikováno v:
Revue d'Épidémiologie et de Santé Publique. 67:S133-S134
Introduction Le CA-125 est un biomarqueur utilise pour le suivi des patientes atteintes d’un cancer des ovaires en situation avancee. Il est utilise pour definir des reponses biologiques au traitement. La meilleure prise en compte de sa dynamique a
Autor:
AS Walker, Andrzej Bienczak, Helen McIlleron, Adrian Cook, Cissy Kityo, Paolo Denti, Lubbe Wiesner, Veronica Mulenga, Diana M. Gibb, Addy Kekitiinwa, David M. Burger
Publikováno v:
Aids, 31, 7, pp. 905-915
Aids, 31, 905-915
Aids, 31, 905-915
Contains fulltext : 169950.pdf (Publisher’s version ) (Closed access) BACKGROUND: Nevirapine is the only nonnucleoside reverse transcriptase inhibitor currently available as a paediatric fixed-dose-combination tablet and is widely used in African c
Autor:
Dan P, Stark, Adrian, Cook, Julia M, Brown, Michael D, Brundage, Andrew C, Embleton, Richard S, Kaplan, Fharat A, Raja, Ann Marie W, Swart, Galina, Velikova, Wendi, Qian, Jonathan A, Ledermann
Publikováno v:
Cancer
BACKGROUND The ICON6 trial showed that cediranib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, improved clinical outcomes for patients with platinum‐sensitive relapsed ovarian cancer when it was used with chemother